title: Ranibizumab for retinal neovascularization.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Jorge
authors.forename: Rodrigo S
authors.initials: RS
authors.lastname: Oliveira
authors.forename: Andre
authors.initials: A
authors.lastname: Messias
authors.forename: Felipe P
authors.initials: FP
authors.lastname: Almeida
authors.forename: Mario L
authors.initials: ML
authors.lastname: Strambe
authors.forename: Rogério A
authors.initials: RA
authors.lastname: Costa
authors.forename: Ingrid U
authors.initials: IU
authors.lastname: Scott
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002199:Capillary Permeability; D005260:Female; D006801:Humans; D008266:Macula Lutea / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab; D015861:Retinal Neovascularization / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000069579:Ranibizumab